Incyte Corporation
http://www.incyte.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Incyte Corporation
Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Could SillaJen Get Back On Track Via M2N's Acquisition?
SillaJen selects another Korean firm as its new owner as trading in its stock continues to be suspended following the probe into its former CEO. But it remains to be seen whether the acquisition can catalyze a business breakthrough and speed up clinical development for the oncolytic immunotherapeutic firm.
Novo Ventures Remains Bullish After ‘Very Active’ Year
In this latest installment of VC playbook, In Vivo speaks to Naveed Siddiqi, senior partner at Novo Ventures. He discusses the group’s strategy, the European investment outlook for life sciences and how COVID-19 has permanently shifted perceptions of the biopharma industry.
Keeping Track: Cloudy Horizon For Teplizumab, Roxadustat; Nuplazid Stumbles Over Subgroups; CAR-T Submissions From Gilead, J&J
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Maxia Pharmaceuticals, Inc.